Key Takeaways
- Volume recovery, value lag: Destocking bottomed out and volumes grew across the board, but lower raw material and finished product prices masked this in the top line.
- China dumping pressures pricing: Chinese producers, back in production but not consumption, are dumping into India and other markets, creating a headwind for DMCC and global peers.
- Capex cycle complete, debt paydown begins: The large capex phase is done and plants are achieving target efficiencies; management is now prioritizing debt repayment over new investments given high interest rates and macro uncertainty.
- Demand recovery pushed out a full year: Management does not expect optimism to return until the interest rate cycle eases and European demand picks up, framing this as a "this whole year" wait.
- What to watch next quarter: Whether the volume recovery converts to value as raw material prices stabilize, any sign of easing in Chinese dumping, and traction on new product approvals if end-user demand firms.
Demand & Pricing Environment
- Destocking cycle bottomed: Large end users stopped or substantially reduced buying in the Oct–Dec quarter as prices fell; in Q4, consumption restarted but has not returned to expected levels, creating a "very sort of soft market scenario."
- Volume growth hidden by price: Volumes were substantially better YoY, but lower pricing of raw materials and finished products meant this was not apparent in the top line; export volume growth in FY23 was at least 61% because prices were lower than the previous year.
- Chinese dumping: Chinese producers are back in production but not consumption, dumping products in India and other markets, creating pricing pressure for DMCC and all Indian, European and American companies.
- End-user demand weak: Discretionary spending has come down across cars, electronics and shirts, affecting downstream industries like textiles, dying, polymers, plastics and pigments.
- Supply chain risk forgotten: Easy logistics and freely available container ship space have made purchasing managers forget supply chain risk, reducing urgency to switch suppliers away from China.
- Europe demand absent: No uptick in demand from Europe for anything currently.
- Logistics costs normalized: Logistics costs came down to almost pre-COVID levels, partly an indication of the global slowdown as container ship space is now freely available.
Goculdas: "Now again because of easy logistics, that whole supply chain risk, all the purchasing managers have forgotten. So, let there be some kind of a consolidation phase. Where there's an uptick in the market, I think there will be much more traction for new products."
Operational Performance
- No shutdown in Q4: Q4 was better than the previous quarter partly because Roha had a shutdown in the prior quarter which affected operations.
- Raw material stability returned: No significant movement in raw material prices in Q4, unlike the Jul–Sep quarter, leading to more stability and better availability.
- Boron availability improved: Supply availability improved in the last quarter with easing of both raw material and logistics constraints; earlier raw materials were not arriving on time.
- Bulk chemicals utilization strong: Above 90% capacity utilization on bulk chemicals; speciality chemicals utilization is lower with room for growth.
- New product traction slowed: In a downtrend, customers don't have time or money to invest in new product approvals; when prices are dropping, they focus on bottom line rather than supplier changes.
- New capacity breakeven slow: The company is slowly breaking even on the recent capex, but the investment was made expecting a much better upside which hasn't materialized.
- Sulfur market: Sulfur prices are substantially lower than peak and stable at the moment.
Goculdas: "Mathematically if your margin remains the same in absolute terms, but your prices come down for both raw materials and finished products, then as a percentage it increases, you may see a better margin at lower prices and then a lower margin at higher prices, but not necessarily in absolute terms."
Capex, Debt & Capital Allocation
- Large capex phase complete: The large part of capital expenditure for the foreseeable future has been done successfully; production levels and efficiencies desired in the plants have been achieved.
- Debt repayment prioritized: Management started paying down some loans, citing high interest rates as making this the more prudent course.
- No major investments near-term: With high uncertainty, the company is not looking at any major large investments; it will wait to generate more operating cash flow and for interest rates to come down before getting aggressive again.
- Capex outlook FY24–FY25 modest: Not a significant number, nothing compared to the last two years.
- Sustainability investments continue: Significant investments made in sustainability; one more project to be completed this year which will reduce carbon footprint again substantially.
- Boron expansion deferred: A significant increase in boron business would require investments the company is not ready to make yet.
Goculdas: "With so much uncertainty right now, we are not looking at any major large investments. If you had a look at the cash flow, we started paying down some of the loans. And I think with the high interest rates and everything, that is more prudent thing to do."
Product Mix & Downstream Potential
- Bulk-speciality split target: Expect the 40:60 bulk-speciality split to move to 30:70 or so going forward, depending on prices.
- Downstream upside: At least 30% to 40% extra can be done on the downstream side after recent expansions at Dahej, per management estimate.
- Downstream revenue potential: At current prices, downstream products quarterly run rate could reach ₹130–140 crores at optimal utilization, up from ~₹100 crores.
- Boron run rate improving: Expect slightly better run rate in coming times due to improved raw material availability and logistics.
- Market readiness: As and when the market turns for speciality chemicals, the company will be there to supply.
- EU carbon tax positioning: Management believes DMCC's carbon footprint would be amongst the lowest in the industry and compared to anybody in China; it is certain this will generate value, just a question of when.
R&D, Technology & Strategic Positioning
- R&D team strengthening: The company is recruiting and strengthening the R&D team.
- R&D spend steady: Will continue at about 1% to 2% of top line "for a while"; no particular target in mind for R&D spend.
- Flow chemistry conviction: Management believes hazardous chemicals and upstream operations would benefit much more from flow chemistry than pharma, given larger volumes and more dangerous chemicals handled.
- Japan–India relationship: Management expects Japan and India to come closer together politically and economically; Japan is threatened by China politically, seeking alternate partners, and looking to invest in other countries' growth.
- Custom synthesis advances: The company has done small cases of customers giving advances for custom synthesis projects, but not in any significant manner.
Goculdas: "In fact, according to me personally, I believe that for the hazardous chemicals, and particularly for upstream, it is more important to go to flow chemistry than the pharma industry, because we are handling larger volumes, more dangerous chemicals, we would benefit much more from movement towards flow chemistry."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Bulk-speciality mix shift | Move from 40:60 to 30:70 split | Going forward, depending on prices |
| Demand recovery | Optimism returns only after interest rate cycle eases and Europe crisis resolves | Not until "this whole year" |
| Downstream utilization upside | At least 30–40% additional volume possible at Dahej | No date (capacity available) |
| Capex | Not a significant number, nothing compared to last two years | FY24–FY25 |
| R&D spend | Continue at 1–2% of top line | "For a while" |
| Sustainability project | One more project to be completed, reducing carbon footprint substantially | This year |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹94 cr, lower than ₹104 cr in Q4 FY22 due to lower pricing, though volumes were substantially better |
| EBITDA | ₹17 cr |
| EBITDA margin | ~18% |
| Profit before tax | ~₹9 cr |
| PBT margin | ~10% |
| Bulk vs speciality chemicals split | 40:60 |
| FY23 exports growth | 61% over FY22 |
| Sulfuric acid plant capacity utilization | 90% and upward |
| Downstream products upside after Dahej expansions | at least 30% to 40% extra (management estimate) |
| Downstream products quarterly run rate potential at optimal capacity | ₹130–140 cr, up from around ₹100 cr (per an analyst's math) |
| R&D spend | 1% to 2% of top line |
| Sulfur required per ton of sulfuric acid | 0.33 or 0.34 tons |